Evidence map›Paper›PMID 40214660›Full record

ReviewHuman vaccines & immunotherapeutics2025

Evaluation of efficacy and effectiveness across the pneumococcal conjugate vaccine era.

David C LaFon

Abstract readReview
In one paragraph

Review in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

David C LaFonDivision of Pulmonary, Allergy, and Critical Care Medicine, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL, USA.ORCID 0000-0001-5174-1931

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pneumococcal conjugate vaccines (PCVs) have resulted in a dramatic reduction in vaccine-type disease in both children and adults. Several expanded PCVs have recently been approved and incorporated into immunization programs for children and adults, with numerous additional vaccine formulations in development or undergoing evaluation in clinical trials. This concise review provides an introduction to the evolving approaches to vaccine evaluation used in the decades since the initial studies of PCV7, followed by a contemporary assessment of challenges and future directions for studies of efficacy, immunogenicity, and real-world effectiveness.

Indexed as

Pneumococcal InfectionsPneumococcal VaccinesVaccine EfficacyAdultChildHumansImmunogenicity, VaccineStreptococcus pneumoniaeVaccines, ConjugatePneumococcal VaccinesVaccines, Conjugateclinical trialsepidemiologyimmunoassaysStreptococcus pneumoniaevaccine response

Identifiers

PMID40214660
PMCPMC12934185

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.